# Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Canonical URL: https://biopharmsignal.com/news/ZURA/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress
Ticker: ZURA
Company: Zura Bio
Source: Zura Bio
Published: 2026-03-05 11:30 EST
Original Source URL: https://investors.zurabio.com
## Summary

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 5, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

## Article Body
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 5, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today
## Recent Company News
- 2026-06-29 11:30 EST — [Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program](https://biopharmsignal.com/news/ZURA/zura-bio-exceeds-enrollment-target-in-both-hidradenitis-suppurativa-hs-systemic--cfd7a19d) — Source: Zura Bio
- 2026-05-14 11:30 EST — [Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6d81197f) — Source: Zura Bio
- 2026-05-13 11:30 EST — [Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer](https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer) — Source: Zura Bio
- 2026-05-07 11:30 EST — [Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-05-04 20:05 EST — [Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Zura Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)